MBX Biosciences has announced its fourth quarter and full-year 2025 financial results, revealing significant advancements in its pipeline for endocrine and metabolic diseases. The company’s lead candidate, canvuparatide, for chronic hypoparathyroidism, is set to enter a Phase 3 clinical trial in Q3 2026 following a successful End-of-Phase 2 meeting with the FDA, marking a crucial step towards potential market entry.

This progress is particularly relevant to the longevity and healthspan research community, as canvuparatide addresses a critical unmet need in chronic hypoparathyroidism, a condition that can significantly impact quality of life. Additionally, MBX’s investment in R&D, which rose to approximately $79.2 million, underscores the growing focus on innovative therapies in metabolic health, reflecting broader trends in the biotech sector.

With a robust cash position expected to support operations through 2029, MBX is well-positioned to advance its pipeline, including promising candidates like imapextide and MBX 4291. For a deeper dive into MBX’s strategic developments and financial outlook, I recommend exploring the full article.

Source: longevity.technology